Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM).
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Martin J. Van Den Bent, Hui Kong Gan, Andrew B. Lassman, Priya Kumthekar, Ryan Merrell, Nicholas A. Butowski, Zarnie Lwin, Tom Mikkelsen, Louis B. Nabors, Kyriakos P. Papadopoulos, Marta Penas-Prado, John Simes, Helen Wheeler, Erica J. Gomez, Ho-Jin Lee, Lisa Roberts-Rapp, Hao Xiong, Earle E. Bain, Kyle D. Holen, David A. Reardon
Institutions: Erasmus MC, Erasmus MC Cancer Institute, Austin Health, Olivia Newton-John Cancer Research Institute, Columbia University Irving Medical Center, Northwestern University, Endeavor Health, University of California, San Francisco, The University of Queensland, Royal Brisbane and Women's Hospital, Henry Ford Health, University of Alabama at Birmingham, South Texas Accelerated Research Therapeutics, The University of Texas MD Anderson Cancer Center, National Health and Medical Research Council, Royal North Shore Hospital, AbbVie (United States), Dana-Farber Cancer Institute
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2714780613